Prurigo Nodularis and Its Management

Claudia Zeidler, Gil Yosipovitch, Sonja Ständer

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Prurigo nodularis occurs with chronic pruritus and the presence of single to multiple symmetrically distributed, hyperkeratotic, and intensively itching nodules. Diverse dermatologic, systemic, neurologic, or psychiatric conditions can lead to prurigo nodularis. Structural analysis demonstrated a reduced intraepidermal nerve fiber density and increased dermal levels of nerve growth factor and neuropeptides such as substance P and calcitonin gene-related peptide. Novel therapy concepts such as inhibitors at neurokinin-1, opioid receptors, and interleukin-31 receptors have been developed. The mainstays of prurigo nodularis therapy comprise topical steroids, capsaicin, calcineurin inhibitors, phototherapy, and the systemic application of anticonvulsants, μ-opioid receptor antagonists, or immunosuppressants.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalDermatologic Clinics
Issue number3
StatePublished - Jul 2018


  • Chronic pruritus
  • Itch
  • Prurigo nodularis
  • Pruritus
  • Scratch lesions
  • Therapy

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Prurigo Nodularis and Its Management'. Together they form a unique fingerprint.

Cite this